miRagen Therapeutics (MGEN) Tops Q3 EPS by 12c

miRagen Therapeutics (NASDAQ: MGEN) reported Q3 EPS of ($0.27), $0.12 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $1.6 million, versus $900 thousand reported last year.

For earnings history and earnings-related data on miRagen Therapeutics (MGEN) click here.

You May Also Be Interested In

• Target (TGT) Tops Q2 EPS by $1.78, Beats on Revenue; Offers FY27 EPS Guidance
• Corporación América Airports S.A. (CAAP) Misses Q2 EPS by 18c
• Ameramex International, Inc. (AMMX) Reports In-Line Q2 EPS